



November 8, 2023

To Whom It May Concern

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President and CEO
(Security Code: 4569, TSE Prime.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-3525-4707

Notice of differences between Forecasts and Actual Results

KYORIN Pharmaceutical Co., Ltd. announced that there were differences between its consolidated financial forecast for secondary quarter of fiscal year (from April 1 to September 30, 2023) disclosed on May 11, 2023, and actual results announced today.

1. Differences between financial forecasts and results for secondary quarter the fiscal year (from April 1 to September 30, 2023)

(Unit: Millions of yen)

	Net sales	Operating Profit	Ordinary Profit	Profit attributable to owners of parent	Basic earnings per share (yen)
Previous forecast (A)	53,700	600	900	700	12.22
Results (B)	54,937	1,144	1,387	1,757	30.66
Change (B-A)	1,237	544	487	1,057	—
Change (%)	+2.3	+90.8	+54.2	+151.1	—

2. Reason of Difference

Operating profit and ordinary profit exceeded the previous forecast due to net sales of new drugs exceeded the forecasts and SG&A expenses failing short of assumed level. The posting of a gain on sale of investment securities of 969 million yen resulted in an increase of profit attributable to owners of parent compared with previous forecast.

The forecast of consolidated results for the full year announced on May 11, 2023 has not been changed.